Quest Diagnostics (DGX) Cost of Revenue (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Cost of Revenue data on file, last reported at $2.0 billion in Q1 2026.

• Quarterly Cost of Revenue rose 9.17% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 billion (up 10.44% YoY) and the FY2025 annual result came in at $7.4 billion, up 11.19% from the prior year.
• Cost of Revenue grew to $2.0 billion in Q1 2026 per DGX's latest filing, from $1.9 billion in the prior quarter.
• The five-year high for Cost of Revenue was $2.0 billion in Q1 2026, with the low at $1.5 billion in Q3 2023.
• Average Cost of Revenue over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2022.
• Year-over-year, Cost of Revenue dropped 8.32% in 2022 and climbed 14.12% in 2025.
• Quest Diagnostics' Cost of Revenue stood at $1.6 billion in 2022, then fell by 1.46% to $1.6 billion in 2023, then climbed by 13.6% to $1.8 billion in 2024, then climbed by 7.54% to $1.9 billion in 2025, then rose by 3.01% to $2.0 billion in 2026.
• Business Quant data shows DGX's Cost of Revenue at $2.0 billion in Q1 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q3 2025.